The Effect of Addition of Metformin In Obese Non- Diabetic Patients With Heart Failure With Preserved Ejection Fraction

Status: Unknown
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Diabetes mellitus people have a higher incidence of cardiovascular disease, and the results of cardiovascular events are worse. Heart failure and diabetes both have a worse prognosis, with a 1.5-2 times increased risk of death. Data from the literature have shown that MET lowers mortality by 14-35% in this patient population, which represents one-third of all HF patients with no increases in lactic acidosis incidence.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 74
Healthy Volunteers: f
View:

⁃ Age of 40 years to 74 years.

• HFpEF (≥ 50%)

• Written informed consent of the subject to participate in the study.

• New York Heart Association functional class II-IV.

• Body mass index ≥ 30 Kg/m2

Locations
Other Locations
Egypt
Cairo University Hospitala
RECRUITING
Cairo
Cairo University Hospitals
NOT_YET_RECRUITING
Cairo
Contact Information
Primary
sara eladawy, PhD
smeladway@msa.edu.eg
01222124567
Backup
naglaa bazan, Ass.Prof
naglaabazan@cu.edu.eg
01005807504
Time Frame
Start Date: 2023-10-01
Completion Date: 2024-12-01
Participants
Target number of participants: 80
Treatments
No_intervention: control
Lifestyle counseling plus standard evidence based therapy
Experimental: intervention (metformin)
Lifestyle counseling plus standard evidence based therapy and metformin (target dose 1000 mg bid)
Sponsors
Collaborators: Cairo University
Leads: Sara ElAdawy

This content was sourced from clinicaltrials.gov